NASDAQ:ENTX

Entera Bio (ENTX) Stock Forecast, Price & News

$0.65

-0.06 (-8.44%)

(As of 09/25/2023 ET)

Compare

Today's Range: $0.57
▼
$0.70
50-Day Range: $0.59
▼
$0.87
52-Week Range: $0.47
▼
$1.48

Volume: 47,371 shs
Average Volume: 109,878 shs
Market Capitalization: $18.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Entera Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,436.1% Upside
$10.00 Price Target
Short Interest: Healthy
0.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$24,000 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.33) to ($0.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

788th out of 962 stocks

Biological Products, Except Diagnostic Industry

126th out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Entera Bio has a forecasted upside of 1,436.1% from its current price of $0.65.
Amount of Analyst Coverage
Entera Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.12% of the float of Entera Bio has been sold short.
Short Interest Ratio / Days to Cover
Entera Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Entera Bio has recently increased by 24.88%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Entera Bio does not currently pay a dividend.
Dividend Growth
Entera Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENTX.

0.6

News and Social Media Coverage

Search Interest
4 people have searched for ENTX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Entera Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.90% of the stock of Entera Bio is held by insiders.
Percentage Held by Institutions
Only 8.92% of the stock of Entera Bio is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Entera Bio are expected to decrease in the coming year, from ($0.33) to ($0.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Entera Bio is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Entera Bio is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Entera Bio has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ENTX Price History

30 days | 90 days | 365 days | Advanced Chart

ENTX Stock News Headlines

September 13, 2023 | finance.yahoo.com

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

September 5, 2023 | finance.yahoo.com

Entera Bio to Participate in Upcoming Investor Conferences

September 26, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 16, 2023 | finance.yahoo.com

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

August 12, 2023 | finanznachrichten.de

Entera Bio Ltd.: Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

August 11, 2023 | finance.yahoo.com

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

June 7, 2023 | finanznachrichten.de

Entera Bio Ltd.: Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

June 7, 2023 | technews.tmcnet.com

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

September 26, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 7, 2023 | finance.yahoo.com

Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)

May 6, 2023 | finanznachrichten.de

Entera Bio Ltd.: Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 5, 2023 | finance.yahoo.com

Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates

May 5, 2023 | msn.com

Entera Bio: Q1 Earnings Insights

May 5, 2023 | finance.yahoo.com

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 3, 2023 | technews.tmcnet.com

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

May 3, 2023 | finance.yahoo.com

Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

April 27, 2023 | marketwatch.com

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

April 26, 2023 | finance.yahoo.com

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board

April 4, 2023 | msn.com

HC Wainwright & Co. Reiterates Entera Bio (ENTX) Buy Recommendation

April 4, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)

April 3, 2023 | finance.yahoo.com

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

March 31, 2023 | finance.yahoo.com

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

March 31, 2023 | finance.yahoo.com

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

March 23, 2023 | finance.yahoo.com

Entera Bio Regains Compliance with Nasdaq Listing Requirements

March 10, 2023 | finance.yahoo.com

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

February 20, 2023 | finance.yahoo.com

Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?

February 15, 2023 | finance.yahoo.com

Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

See More Headlines

Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Company Calendar

Last Earnings: 8/11/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ENTX
CUSIP: N/A
CIK: 1638097
Web: www.enterabio.com
Phone: (722) 532-7151
Fax: N/A
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +1,436.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,070,000.00
Net Margins: -9,754.48%
Pretax Margin: -47,586.36%
Return on Equity: -95.70%
Return on Assets: -83.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.26
Quick Ratio: 5.26

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 144.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 1.59

Miscellaneous

Outstanding Shares: 28,800,000
Free Float: 26,240,000
Market Cap: $18.75 million
Optionable: Not Optionable
Beta: 1.84

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Ms. Miranda J. Toledano M.B.A. (Age 46)
CEO & Director
Comp: $412.5k

Dr. Hillel Galitzer M.B.A. (Age 45)
Ph.D., Chief Operating Officer
Comp: $387k

Ms. Dana Yaacov-Garbeli CPA (Age 40)
Chief Financial Officer

Dr. Arthur C. Santora II (Age 72)
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENTX Stock - Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings or view top-rated stocks.
What is Entera Bio's stock price forecast for 2023?: 1 Wall Street analysts have issued 12 month target prices for Entera Bio's shares. Their ENTX share price forecasts range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,436.1% from the stock's current price.
View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts.
How have ENTX shares performed in 2023?: Entera Bio's stock was trading at $0.73 on January 1st, 2023. Since then, ENTX shares have decreased by 10.8% and is now trading at $0.6510.
View the best growth stocks for 2023 here.
Are investors shorting Entera Bio?: Entera Bio saw a increase in short interest in August. As of August 31st, there was short interest totaling 26,600 shares, an increase of 24.9% from the August 15th total of 21,300 shares. Based on an average trading volume of 32,100 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's stock are short sold.
View Entera Bio's Short Interest.
When is Entera Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ENTX earnings forecast.
How were Entera Bio's earnings last quarter?: Entera Bio Ltd. (NASDAQ:ENTX) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. Entera Bio had a negative trailing twelve-month return on equity of 95.70% and a negative net margin of 9,754.48%.

What other stocks do shareholders of Entera Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).
When did Entera Bio IPO?: (ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.
What is Entera Bio's stock symbol?: Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."
Who are Entera Bio's major shareholders?: Entera Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca.
View institutional ownership trends.
How do I buy shares of Entera Bio?: Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Entera Bio's stock price today?: One share of ENTX stock can currently be purchased for approximately $0.65.
How much money does Entera Bio make?: Entera Bio (NASDAQ:ENTX) has a market capitalization of $18.75 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.
How can I contact Entera Bio?: Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.

This page (NASDAQ:ENTX) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial